Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Kintara Therapeutics, Inc. (KTRA : NSDQ)
 
 • Company Description   
Kintara Therapeutics Inc. is a biopharmaceutical company. It is focused on the development of new solid tumor cancer therapies. The company's program includes VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer, which are in clinical stage. Kintara Therapeutics Inc. is based in San Diego, California.

Number of Employees: 4

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.16 Daily Weekly Monthly
20 Day Moving Average: 5,023,029 shares
Shares Outstanding: 65.53 (millions)
Market Capitalization: $10.24 (millions)
Beta: 1.69
52 Week High: $2.85
52 Week Low: $0.14
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -44.71% -39.46%
12 Week -57.78% -52.55%
Year To Date -69.37% -62.58%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9920 PACIFIC HEIGHTS BLVD SUITE 150
-
SAN DIEGO,CA 92121
USA
ph: 858-350-4364
fax: 604-608-5685
ir@kintara.com http://www.kintara.com
 
 • General Corporate Information   
Officers
Saiid Zarrabian - Chief Executive Officer and Director
Robert E. Hoffman - Chairman of the Board
Dennis Brown, PhD - Chief Scientific Officer
Scott Praill - Chief Financial Officer
Robert J. Toth, Jr. - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 49720K101
SIC: 2834
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 10/05/22
Share - Related Items
Shares Outstanding: 65.53
Most Recent Split Date: 5.00 (0.10:1)
Beta: 1.69
Market Capitalization: $10.24 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.59 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 10/05/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 52.17%
vs. Previous Quarter: 8.33%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -144.27
12/31/21 - -139.26
09/30/21 - -131.58
Current Ratio
03/31/22 - 3.12
12/31/21 - 4.36
09/30/21 - 6.70
Quick Ratio
03/31/22 - 3.12
12/31/21 - 4.36
09/30/21 - 6.70
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -0.06
12/31/21 - 0.03
09/30/21 - 0.11
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©